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BACKGROUND: A major obstacle to the successful management of pancreatic cancer is to acquire resistance to the existing
chemotherapeutic agents. Resistance to gemcitabine, the standard first-line chemotherapeutic agent for advanced and metastatic
pancreatic cancer, is mainly attributed to an altered apoptotic threshold in the pancreatic cancer. The MUC4 transmembrane
glycoprotein is aberrantly overexpressed in the pancreatic cancer and recently, has been shown to increase pancreatic tumour cell
growth by the inhibition of apoptosis.
METHODS: Effect of MUC4 on pancreatic cancer cells resistance to gemcitabine was studied in MUC4-expressing and
MUC4-knocked down pancreatic cancer cell lines after treatment with gemcitabine by Annexin-V staining, DNA fragmentation
assay, assessment of mitochondrial cytochrome c release, immunoblotting and co-immunoprecipitation techniques.
RESULTS: Annexin-V staining and DNA fragmentation experiment demonstrated that MUC4 protects CD18/HPAF pancreatic cancer
cells from gemcitabine-induced apoptosis. In concert with these results, MUC4 also attenuated mitochondrial cytochrome c release
and the activation of caspase-9. Further, our results showed that MUC4 exerts anti-apoptotic function through HER2/extracellular
signal-regulated kinase-dependent phosphorylation and inactivation of the pro-apoptotic protein Bad.
CONCLUSION: Our results elucidate the function of MUC4 in imparting resistance to pancreatic cancer cells against gemcitabine
through the activation of anti-apoptotic pathways and, thereby, promoting cell survival.
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Pancreatic adenocarcinoma is among the most common causes
for cancer-related deaths in western countries (Keighley, 2003).
It is one of the neoplasms with an extremely poor prognosis
because of its aggressive invasion, early metastasis, resistance
to existing chemotherapeutic agents and radiation therapy
(Bardeesy and DePinho, 2002). Despite an enormous amount of
effort spent in the development of chemotherapies for pancreatic
cancer, these are effective only in a small proportion of patients.
Gemcitabine has become the standard first-line chemotherapeutic
agent for the advanced and metastatic pancreatic cancer, with
marginal survival advantage, and amelioration of disease-related
symptoms (El-Rayes and Philip, 2003; Pino et al, 2004). In
contrast, resistance to gemcitabine has been increasing in recent
years, and the effectiveness of gemcitabine has been reduced to
o20% (Wheatley and McNeish, 2005). It is considered that
resistance to gemcitabine treatment is mainly attributed to an
altered apoptotic threshold in pancreatic cancer cells (Schniewind
et al, 2004).
MUC4, a membrane-bound mucin, is involved in the regulation
of cell proliferation and inhibition of apoptosis (Chaturvedi et al,
2007). To date, the aberrant overexpression of MUC4 has
been reported in pancreatic malignancies, but not in the normal
pancreas, which has made MUC4 a promising therapeutic
target for anti-cancer adjuvant therapies (Andrianifahanana et al,
2001). Recently, we have shown that the overexpression of
MUC4 in mouse embryonic fibroblast cells confers oncogenic
transformation (Bafna et al, 2008). In addition, studies by
overexpression and down-regulation of MUC4 in various
pancreatic cancer cells showed its involvement in the development
and progression of pancreatic cancer (Singh et al, 2004; Chaturvedi
et al, 2007; Moniaux et al, 2007). Importantly, our recent
studies have revealed that MUC4 interacts with HER2, a member
of epidermal growth factor (EGF) receptor family and regulates
its expression by post-translational mechanisms (Chaturvedi et al,
2008). HER2 is an established oncoprotein and is involved in
growth and malignant properties of the cancer cells through
activation of various intracellular signalling pathways (Hsieh and
Moasser, 2007). It has been shown that the EGF protects
prostate cancer cells from apoptosis by phosphorylating apoptotic
protein Bad through extracellular signal-regulated kinase (ERK)
activation (Sastry et al, 2006). In our earlier studies, MUC4 has
been shown to increase the phosphorylation of ERK by stabiliza-
tion of the expression of HER2 in pancreatic cancer cells (Bafna
et al, 2008; Chaturvedi et al, 2008). These findings indicate that
MUC4 might be responsible for resistance to gemcitabine
treatment by alteration of apoptotic threshold in pancreatic
cancer cells.
In this study, we performed a set of experiments to define the
function of MUC4 in the activation of anti-apoptotic pathways in
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MUC4-down-regulated CD18/HPAF cells (CD18/HPAF/siMUC4) and
scrambled siRNA-transfected CD18/HPAF cells (CD18/HPAF/Scr)
were treated with gemcitabine for 24 and 48h and extent of apoptosis
was measured. Annexin-V staining showed that MUC4 inhibited
gemcitabine-induced apoptosis of CD18/HPAF/Scr pancreatic cancer
cells. CD18/HPAF/Scr cells also showed reduced DNA fragmentation,
a hallmark of apoptosis, compared with CD18/HPAF/siMUC4 cells. In
concert with this, the release of mitochondrial cytochrome c and the
activation of caspase-9 were attenuated in MUC4-expressing CD18/
HPAF/Scr cells compared with MUC4-down-regulated CD18/HPAF/
siMUC4 cells. Interestingly, the expression of MUC4 was associated
with the increased level of phospho-HER2 and -ERK, which further
leads to deactivation of apoptotic protein Bad through enhancing its
phosphorylation. Taken together, these findings indicate that aberrant
overexpression of MUC4 in pancreatic cancer contributes resistance
to chemotherapeutic agent gemcitabine by activation of MUC4-
HER2-mediated anti-apoptotic pathway.
MATERIALS AND METHODS
Cell culture
Earlier generated MUC4-knocked down CD18/HPAF pancreatic
cancer cell line (CD18/HPAF/siMUC4) and control CD18/HPAF
(CD18/HPAF/Scr) cells (Chaturvedi et al, 2007) were cultured in
DMEM supplemented with 10% foetal bovine serum and
antibiotics (penicillin and streptomycin 100mgml
–1). Cells were
grown at 371C with 5% CO2 in a humidified atmosphere.
Measurement of apoptosis
Apoptosis was measured by using the Annexin-V Fluos staining kit
(Roche Diagnostics, Indianapolis, IN, USA). For this, 1.510
6 cells
each of CD18/siMUC4 and control CD18/Scr were cultured in
10cm petridishes followed by overnight incubation at 371C. The
cells were then treated with 1mM gemcitabine (Symon et al, 2002)
in 10% DMEM for 24 and 48h, respectively, followed by 24h
incubation in 10% DMEM. The induction of apoptosis and
necrosis was measured by staining the cells with Annexin-V and
propidium iodide solution, followed by fluorescence-activated cell
sorting analysis (FACs).
Assessment of mitochondrial cytochrome c release
Cytosolic fraction was prepared as described by Kharbanda et al
(1997). Briefly, cells were washed twice with PBS, and the pellet of
1.510
6 was suspended in 1ml of ice-cold buffer A (20mM Hepes,
pH 7.5/1.5mM, MgCl2/10mM, KCl/1mM, EDTA/1mM, EGTA/1mM,
DTT/0.1mM, phenylmethylsulfonyl fluoride and 1protease
inhibitor cocktail (Roche)) containing 250mM sucrose. The
cells were homogenized by douncing three times in a dounce
homogenizer with a sandpaper-polished pestle. After centrifuga-
tion for 5min at 41C, the supernatants were ultracentrifuged at
105000g for 30min at 41C. The resulting supernatant was used
as the soluble cytosolic fraction. Protein concentrations in the
soluble cytosolic fractions were determined using a Bio-RadD/C
protein estimation kit. The same amount of protein from the
cytosolic fractions of CD18/Scr and CD18/siMUC4 cells were used
to quantify the release of cytochrome c from mitochondria, using a
commercially available cytochrome c ELISA kit (Calbiochem, San
Diego, CA, USA) according to the manufacturer’s instructions.
DNA fragmentation assay
CD18/HPAF/Scr and CD18/HPAF/siMUC4 cells were cultured in 10%
DMEM with and without 1mM of gemcitabine. Treated cells were
washed twice with PBS, and DNA was extracted using Gentra’s
Puregene DNA Isolation Kit (Qiagen, Valencia, CA, USA) protocol. A
measure of 5mg of isolated DNA was resolved on a 1% agarose gel.
Immunoblot analysis
Gemcitabine-treated and -untreated CD18/HPAF/Scr and CD18/
HPAF/siMUC4 cells were processed for protein extraction and
western blotting using standard procedures. Cell lysates were
prepared as described earlier (Bafna et al, 2008). Protein concen-
trations were determined using a Bio-RadD/C protein estimation
kit. For MUC4, the proteins (20mg) were resolved by electro-
phoresis on a 2% SDS–agarose gel under reducing condi-
tions. For b-actin, HER2, p
1248HER2, ERK1/2 and pERK1/2,
SDS–PAGE (10%) was performed under similar conditions. For
Bad, pBad and caspase-9, SDS–PAGE (15%) was performed under
similar conditions. Resolved proteins were transferred onto the
polyvinylidene difluoride membrane and blocked in 5% non-fat
milk in phosphate-buffered saline (PBS) for 2h and subjected to
the standard immunodetection procedure using specific antibo-
dies. For b-actin immunodetection, anti-b-actin mouse mono-
clonal antibody (Sigma, St Louis, MO, USA) in dilution of 1:5000
(used as internal control) was used; and for MUC4 immunodetec-
tion, anti-MUC4 mouse monoclonal antibody (8G7, generated in
our laboratory) in dilution of 1:1000 was used. For HER2,
p
1248HER2, ERK, pERK and caspase-9 immunodetection, anti-
ErbB2 rabbit polyclonal antibody (Santa Crutz Biotecnology, Santa
Cruz, CA, USA), anti-p
1248ErbB2 rabbit polyclonal antibody
(Upstate, San Francisco, CA, USA), anti-ERK1/2 rabbit polyclonal
antibody (Santa Crutz Biotecnology), anti-pERK1/2 rabbit poly-
clonal antibody (Cell Signaling Technology Inc, Danvers, MA,
USA) and anti-caspase-9 mouse monoclonal antibody (Cell
Signaling Technology Inc) in dilution of 1:1000 were used,
respectively. For 14-3-3, Bad and pBad immunodetection, anti-
14-3-3 mouse monoclonal antibody in dilution of 1:250 (Santa
Crutz Biotecnology), anti-Bad mouse monoclonal antibody in
dilution of 1:500 (Santa Crutz Biotecnology) and anti-pBad goat
polyclonal antibody in dilution of 1:200 (Santa Crutz Biotecnology)
were used, respectively. The membranes were incubated for 4h at
room temperature, followed by 610min washes in TBST (50mM
Tris–HCl, pH 7.4, 150mM NaCl and 0.05% Tween-20). Further, the
membranes were incubated in Horseradish peroxidase-conjugated
secondary antibodies (Amersham Biosciences, Buckinghamshire,
UK) (diluted at 1:2000 in PBS) for 1h at room temperature,
followed by four washes in TBST. The blots were processed with
ECL Chemiluminescence kit (Amersham Biosciences), and the
signal was detected by exposing the processed blots to X-ray films
(Biomax Films, Kodak, NY, USA).
Co-immunoprecipitation
Cells were grown to 50–60% confluency and treated with 1mM
gemcitabine for 48h in 5% CO2 incubator at 371C. Cells were
washed once with ice-cold PBS and then lysed in extraction buffer,
which contains 1% Triton X-100 in lysis buffer (150mM NaCl,
2m M EDTA, 50mM Tris–Cl (pH 8.0), 1mM NaF, 1mM sodium
orthovanadate, 1mM PMSF, 5mg of aprotinin per ml and 5mgo f
leupeptin per ml) for 25–35min at 41C. The lysates were
centrifuged at 16000g for 30min at 41C. Protein concentrations
were determined using a Bio-RadD/C protein estimation kit. Equal
amounts of protein cell lysates were incubated overnight with anti-
14-3-3 mAbs or IgG in a 500-ml total volume. Protein G-Sepharose
beads (Oncogene Research, Boston, MA, USA) were added to the
lysate–antibody mix and incubated on a rotating platform for 2.5–
3.5h at 41C, followed by three to four washes with the lysis buffer.
The immunoprecipitates or total cell lysates were then immuno-
blotted with anti-14-3-3 mouse monoclonal antibody and anti-
pBad goat polyclonal antibody.
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MUC4 confers resistance to gemcitabine-induced apoptosis
in pancreatic cancer cells
Membrane-bound mucin MUC1 and rat Muc4 have been shown to
inhibit apoptosis induced by multiple insults in rat 3Y1 fibroblast
cells and human melanoma and breast cancer cells, respectively
(Raina et al, 2004; Workman et al, 2009). Anti-apoptotic function
of MUC4 in pancreatic cancer cells in response to serum starvation
has also been observed earlier in our laboratory (Chaturvedi et al,
2007). Further, an altered apoptotic threshold is considered to be
one of the major attribute for the development of resistance to
gemcitabine treatment in pancreatic cancer cells (Schniewind et al,
2004). Therefore, to determine the function of MUC4 in the
development of resistance to gemcitabine in pancreatic cancer
cells, we assessed the effect of MUC4 down-regulation on
gemcitabine-induced apoptosis in CD18/HPAF pancreatic cancer
cells. MUC4 was stably down-regulated in CD18/HPAF pancreatic
cancer cells, which express high level of MUC4, by MUC4 siRNA
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Figure 1 Assessment of function of MUC4 in resistance to gemcitabine-induced apoptosis in CD18/HPAF pancreatic cancer cells. MUC4 was down-
regulated in CD18/HPAF cells (CD18/HPAF/siMUC4) by using siRNA technology earlier in our laboratory (Chaturvedi et al, 2007). Scrambled siRNA-
transfected CD18/HPAF cells (CD18/HPAF/Scr) were used as a control. (A) Western blot analysis was carried out to measure the expression of MUC4. A
total of 20mg protein from cell extracts was resolved by electrophoresis on a 2% SDS–agarose gel, transferred to polyvinylidene difluoride membrane and
immunoblotted with anti-MUC4 mAb (8G7). The membrane was then probed with horseradish peroxidase-labelled goat anti-mouse immunoglobulin.
Immunoblot of b-actin, obtained from 10% SDS–PAGE, was used as an internal control. Further, these cells were used for measurement of apoptosis. (B)
Cells were seeded in 10cm petridishes and treated with 1mM gemcitabine for 24 and 48h. The cells were then stained with PI and Annexin-V and
percentage of cells undergoing apoptosis was analysed by FACs. Bottom left quadrant, being negative for both Annexin-V and propidium iodide, shows the
live cells; bottom right quadrant, being Annexin-V positive and propidium iodide negative, shows the early apoptotic cells; top right quadrant, being both
propidium iodide positive and Annexin-V positive, shows the late apoptotic or necrotic cells. The results are expressed as the percentage (Mean±s.e.) of
apoptotic cells for CD18/HPAF/siMUC4 cells compared with CD18/HPAF/Scr cells after treating the cells with 1mM gemcitabine for 24 and 48h. MUC4
protects CD18/HPAF cells from gemcitabine-induced apoptosis.
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quantitated for MUC4 expression by immunoblot analysis
(Figure 1A). Scrambled siRNA-transfected CD18/HPAF cells
(CD18/HPAF/Scr) were used as a control. These cell lines were
further used to study the effect of MUC4 on gemcitabine-induced
apoptosis. To analyse the apoptotic index, the MUC4-overexpres-
sing and MUC4-silenced cells were treated with gemcitabine for 24
and 48h and the extent of apoptosis was determined by Annexin-V
and propidium iodide staining followed by flow cytometric
analysis. The results showed that gemcitabine treatment at both
time points was directly associated with apoptosis in CD18/HPAF/
siMUC4 cells and this response was suppressed in CD18/HPAF/Scr
cells (Figure 1B).
Further, DNA fragmentation, which is a hallmark of apoptosis,
was checked in these cell lines. For this, genomic DNA was isolated
from CD18/HPAF/Scr and CD18/HPAF/siMUC4 cells before and
after treatment with gemcitabine and resolved on 1% agarose gel.
Our results showed that MUC4-expressing CD18/HPAF/Scr
exhibited reduced DNA fragmentation compared with MUC4-
silenced CD18/HPAF/siMUC4 cells (Figure 2). These observations
corroborated the finding that MUC4 protects CD18/HPAF
pancreatic cancer cells from gemcitabine-induced apoptosis.
MUC4 blocks activation of intrinsic apoptotic pathway
The balance among the pro and anti-apoptotic members of the
Bcl-2 family proteins has a central function in the regulation of
intrinsic apoptotic pathway by controlling the activation of
mitochondrial cytochrome c release in the cytosol. The mitochon-
drial associated anti-apoptotic proteins Bcl-2 and Bcl-XL suppress
intrinsic mitochondrial apoptotic pathway, whereas pro-apoptotic
proteins, such as Bad, translocate to mitochondria in response to
apoptotic signals and interact with and deactivate Bcl-2 and Bcl-XL
(Yang et al, 1995; Thomadaki and Scorilas, 2006). The pro-
apoptotic activity of Bad is suppressed by its phosphorylation on
serine residues in response to survival signalling cascades. As
M      1       2      3       4       5       6
M. Marker
1. CD18/HPAF/Scr 
2. CD18/HPAF/siMUC4 
3. CD18/HPAF/Scr 1M gemcitabine 24 h
4. CD18/HPAF/siMUC4 1M gemcitabine 24 h
5. CD18/HPAF/Scr 1M gemcitabine 48 h
6. CD18/HPAF/siMUC4 1M gemcitabine 48 h
Figure 2 Determination of DNA fragmentation in response to gemcitabine treatment of CD18/HPAF/Scr and CD18/HPAF/siMUC4 cells. Cells were
seeded in 10cm petridishes and treated without and with 1mM gemcitabine for 24 and 48h. Further, genomic DNA was isolated and 5mg of isolated DNA
resolved on 1% agarose gel. MUC4-expressing CD18/HPAF/Scr cells exhibit reduced DNA fragmentation compared with CD18/HPAF/siMUC4 cells.
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Figure 3 Assessment of intrinsic apoptotic pathway in CD18/HPAF/Scr and CD18/HPAF/siMUC4 cells in response to gemcitabine treatment. (A) Cells
were seeded in 10cm petridishes and treated with 1mM gemcitabine for 48h as described in methodology. A total of 50mg protein from each cell extract
was resolved by SDS–PAGE (15%), followed by immunobloting with anti-pBad, anti-Bad and anti-b-actin (internal control) antibodies. pBad protein level
was more in CD18/HPAF/Scr cells compared with CD18/HPAF/siMUC4 cells. (B) Cytosolic fractions were prepared from 1mM gemcitabine-treated CD18/
HPAF/Scr and CD18/HPAF/siMUC4 cells. The amount of cytochrome c protein from each fraction was then measured with a commercially available
cytochrome c ELISA kit. Level of cytochrome c in the cytosol of CD18/HPAF/siMUC4 was more compared with CD18/HPAF/Scr cells. (C) A total of 20mg
protein from each cell lines treated with 1mM gemcitabine for 48h was resolved by SDS–PAGE (10%), followed by immunobloting with antibodies against
cleaved caspase-9 and b-actin (internal control). CD18/HPAF/siMUC4 cells showed more cleaved caspase-9 compared with CD18/HPAF/Scr cells. These
findings indicate up-regulation of intrinsic apoptotic pathway in CD18/HPAF/Scr cells.
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assess the effect of MUC4, we examined expression of these
proteins in our cell models CD18/HPAF/Scr and CD18/HPAF/
siMUC4 after treatment with gemcitabine. We found that MUC4
markedly increased level of phosphorylated Bad in CD18/HPAF/
Scr cells (Figure 3A). No difference was observed in Bad protein
levels between CD18/HPAF/Scr and CD18/HPAF/siMUC4 cells
(Figure 3A). MUC1 and rat Muc4 has been shown to decrease
apoptosis in response to various insults also by enhancing the
expression of Bcl-XL (Raina et al, 2006; Thomadaki and Scorilas,
2006; Workman et al, 2009). In contrast, we did not observe any
difference in Bcl-XL protein levels after gemcitabine treatment of
CD18/HPAF/Scr and CD18/HPAF/siMUC4 cells (data not shown).
Further, to determine the downstream effect of phosphorylated
Bad on activation of the intrinsic mitochondrial apoptotic path-
way, we examined the release of mitochondrial cytochrome c into
cytosol and the activation of caspase-9. In response to gemcitabine
treatment, mitochondrial cytochrome c release was significantly
increased in MUC4-silenced CD18/HPAF/siMUC4 cells compared
with CD18/HPAF/Scr cells (Figure 3B). In concert with this, the
level of cleaved caspase-9 protein was also enhanced in CD18/
HPAF/siMUC4 cells (Figure 3C). These observations suggest that
MUC4 blocks activation intrinsic mitochondrial apoptotic pathway
in CD18/HPAF pancreatic cancer cells in response to gemcitabine
treatment.
MUC4 facilitates sequestration of Bad in the cytosol
Phosphorylation of Bad promotes its interaction with the
scaffolding protein 14-3-3 and prevents its interaction with anti-
apoptotic Bcl-XL protein, leading to its sequestration in the cytosol
and inhibition of its pro-apoptotic activity (Thomadaki and
Scorilas, 2006). We found that MUC4 increases phosphorylation
of Bad in CD18/HPAF/Scr cells in response to gemcitabine
treatment. Here, we determined that whether increased phospho-
rylation of Bad was associated with the increased binding with
14-3-3 proteins. For this, we performed co-immunoprecipitation
experiment for pBad and 14-3-3 proteins. Our data showed that
pBad was pulled down in 14-3-3 immunoprecipitates in 1mM
gemcitabine-treated CD18/HPAF/Scr cells (Figure 4). Pull down of
pBad in 14-3-3 immunoprecipitates was decreased in CD18/HPAF/
siMUC4 cells after treatment with 1mM gemcitabine (Figure 4).
This suggests that the expression of MUC4 promotes binding of
Bad with 14-3-3 proteins and thereby helps in its sequestration in
the cytosol.
MUC4 activates HER2 downstream signalling pathway
Our recent studies have revealed that MUC4 interacts with HER2,
a member of EGF receptor family and regulates its expression
by post-translational mechanisms (Chaturvedi et al, 2008). To
determine whether MUC4 exerts its anti-apoptotic function in
pancreatic cancer cells through HER2, we examined the expression
and activation of HER2 and its downstream signalling proteins.
Our results showed increased expression and activation of HER2 in
CD18/HPAF/Scr cells compared with CD18/HPAF/siMUC4 cells in
response to gemcitabine treatment (Figure 5). Enhanced activation
of HER2 was also associated with enhanced activation of ERK
(Figure 5). This indicates that MUC4 contributes resistance to
chemotherapeutic agent gemcitabine in CD18/HPAF pancreatic
cancer cells by activation of the MUC4-HER2-mediated anti-
apoptotic pathway.
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Figure 4 Analysis of interaction between pBad and 14-3-3 proteins in
CD18/HPAF/Scr and CD18/HPAF/siMUC4 cells in response to gemcita-
bine treatment by co-immunoprecipiation assay. Lysates from 1mM
gemcitabine-treated and -untreated CD18/HPAF/Scr and CD18/HPAF/
siMUC4 cells were used for immunoprecipitation with mouse anti-14-3-3
antibody. The immunoprecipitates were electrophoretically resolved on a
15% polyacrylamide gel and immunoblotted with anti-14-3-3 and anti-pBad
antibodies. The mouse IgG was used as isotype control for co-
immunoprecipitation study. CD18/HPAF/Scr cells showed enhanced
precipitation of pBad with 14-3-3 proteins in response to gemcitabine
treatment compared with CD18/HPAF/siMUC4 cells.
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Figure 5 Assessment of activation of HER2 and ERK in CD18/HPAF/Scr
and CD18/HPAF/siMUC4 cells in response to gemcitabine treatment. A
total of 1.510
6 cells were seeded in 10cm petridishes and treated with
1mM gemcitabine for 48h. A measure of 20mg of whole cell lysate was
resolved by SDS–PAGE (10%), followed by immunoblotting with
transferred antibodies against HER2, pHER2, ERK, pERK and b-actin
(internal control). CD18/HPAF/Scr cells showed increased expression of
HER2 and also enhanced phosphorylation of HER2 and ERK compared
with CD18/HPAF/siMUC4 cells.
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Our earlier studies have shown the specific and differential
expression of MUC4 in pancreatic adenocarcinoma as compared
with the normal pancreas or chronic pancreatitis (Andrianifaha-
nana et al, 2001). Using MUC4-knockdown and overexpression
pancreatic cancer cell models, we have shown that MUC4
potentiates pancreatic tumour cell growth and metastasis by
altering the behavioural properties of the tumour cells (Singh et al,
2004; Chaturvedi et al, 2007; Moniaux et al, 2007). Recently, the
anti-apoptotic function of MUC4 in pancreatic cancer cells has
been observed in our laboratory (Chaturvedi et al, 2007). Further,
another membrane-bound mucin MUC1 and rat Muc4 have also
been shown to inhibit apoptosis induced by multiple insults in rat
3Y1 fibroblast cells and human melanoma and breast cancer cells,
respectively (Raina et al, 2004; Workman et al, 2009). In addition,
Muc4 has been shown to impart resistance to the trastuzumab
chemotherapeutic agent in breast cancer cells by causing steric
interference with the drug (Price-Schiavi et al, 2002; Nagy et al,
2005). Here, in this study, we explored the function of MUC4 in
development of resistance to gemcitabine in pancreatic cancer
cells. We have shown that overexpression of MUC4 in pancreatic
cancer cells contributes resistance to gemcitabine by activation of
an anti-apoptotic pathway. This makes MUC4 an ideal candidate
to consider as an important marker for prediction of patient
response to therapy.
A membrane-bound mucin MUC1 has been shown to impart
resistance to rat fibroblast cells against gemcitabine by induction
of the intrinsic apoptotic pathway (Raina et al, 2004). Rat Muc4
also provided resistance to chemotherapeutic agent cisplatin in
melanoma and breast cancer cells (Workman et al, 2009).
Consistent with these findings, our data also showed that MUC4
activates intrinsic mitochondrial apoptotic pathways to impart
resistance to gemcitabine in CD18/HPAF pancreatic cancer cells.
We have observed increased phosphorylation of pro-apoptotic
protein Bad in MUC4-expressing CD18/HPAF cells in response to
gemcitabine treatment. No change was observed in the expression
of anti-apoptotic protein Bcl-XL, which has been shown to be a
major player in the inhibition of intrinsic apoptotic pathway in
response to various insults in earlier studies. The mitochondrial-
associated anti-apoptotic proteins Bcl-2 and Bcl-XL suppress
intrinsic mitochondrial apoptotic pathway, whereas pro-apoptotic
proteins, such as Bad, translocate to mitochondria in response to
apoptotic signals, and interact with and deactivate Bcl-2 and
Bcl-XL (Yang et al, 1995; Thomadaki and Scorilas, 2006). The pro-
apoptotic activity of Bad is suppressed by its phosphorylation on
serine residues in response to survival signalling cascades. Indeed,
phosphorylation at serine residue of Bad is sufficient for binding
with scaffolding protein 14-3-3 and thus, inhibits pro-apoptotic
function of Bad. MUC4 causes increased phosphorylation of Bad
in response to gemcitabine treatment of pancreatic cancer cells,
and thereby facilitates increased binding with 14-3-3 proteins.
Therefore, Bad will not translocate to mitochondria to deactivate
the anti-apoptotic protein Bcl-XL. As expected, anti-apoptotic
effects of Bad phosphorylation were also associated with decreased
mitochondrial cytochrome c release in the cytosol for the induc-
tion of intrinsic apoptosis. These findings indicate that MUC4-
mediated increased phosphorylation of Bad is sufficient to protect
pancreatic cancer cells from gemcitabine-induced apoptosis.
Our recent studies have revealed that MUC4 interacts with HER2, a
member of EGF receptor family and regulates its expression by post-
translational mechanisms (Chaturvedi et al, 2008). In addition, a
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Figure 6 Proposed model for possible mechanism of MUC4-mediated resistance to apoptosis. In a viable cell, the pro-apoptotic Bcl-2 family members
(Bax, Bak) and BH3-only proteins, such as Bad, are antagonized by anti-apoptotic members, such as Bcl-XL, Bcl-2. In response to an apoptotic stimulus, Bad
are activated and prevent anti-apoptotic Bcl-2 members from inhibiting pro-apoptotic members. Pro-apoptotic members then form pores into the
mitochondrial membrane and release pro-apoptotic factors, such as cytochrome c into the cytosol, which subsequently activates the caspase cascade leading
to apoptosis. In response to the gemcitabine treatment in CD18/HPAF/Scr MUC4-expressing pancreatic cancer cells, MUC4 phosphorylates anti-apoptotic
protein Bad through MUC4-HER2-ERK-mediated pathway. Phosphorylation of Bad facilitates its binding with scaffolding protein 14-3-3 and, thereby, inhibits
translocation of Bad to the mitochondria to deactivate the anti-apoptotic protein Bcl-XL. These findings suggest that MUC4-mediated increased
phosphorylation of Bad through HER2/ERK pathway might be responsible to protect pancreatic cancer cells from the gemcitabine-induced apoptosis.
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independent of ErbB2/HER2 in A375 melanoma and MCF-7 breast
cancer cells, whereas dependent on ErbB2 in JIMT-1 breast cancer
cells (Workman et al, 2009). Our data showed increased expression
and activation of HER2 in CD18/HPAF/Scr pancreatic cancer cells in
response to gemcitabine treatment. Earlier studies have shown that
MUC4-HER2 interaction subsequently leads to activation of ERK
(Chaturvedi et al, 2008). We have also shown increased activation of
ERK in response to gemcitabine treatment of CD18/HPAF/Scr cells.
Further, ERK activation has been shown to protect prostate cancer
cells from apoptosis by phosphorylating apoptotic protein Bad
(Sastry et al, 2006). These observations suggest that activation of anti-
apoptotic pathway through MUC4-HER2-ERK-mediated pathway
might be responsible for contribution of resistance to chemother-
apeutic agent gemcitabine. A schematic model (Figure 6) has been
proposed to depict the possible mechanism of MUC4-mediated
inhibition of apoptosis in pancreatic cancer cells in response to
gemcitabine treatment.
In conclusion, our data provide the first evidence that MUC4
imparts resistance to gemcitabine in pancreatic cancer cells. We
showed that MUC4 protects CD18/HPAF pancreatic cancer cells
from gemcitabine-induced apoptosis. Furthermore, inhibition of
apoptosis was associated with increased phosphorylation of HER2
and ERK. Activated ERK then deactivates pro-apoptotic protein
Bad by phosphorylation and, thereby, protects cells from
apoptosis. These findings indicate that the overexpression of
MUC4 confers resistance to anti-cancer agent gemcitabine. In the
future, it will be of interest to examine the effect of gemcitabine
treatment on MUC4-expressing and non-expressing pancreatic
cancer cell lines in vivo to support the pathogenic relevance of
MUC4 with the acquisition of resistance to chemotherapeutics.
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